Pembrolizumab for advanced Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests pembrolizumab as a first treatment for advanced classical Hodgkin lymphoma. It may help patients who have not received any prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have advanced stage classical Hodgkin lymphoma.
- You have not had any previous treatment for this type of lymphoma.
- You do not have nodular lymphocyte-predominant Hodgkin lymphoma or a mixed lymphoma type.
- You have not had chemotherapy or radiation therapy in the past.
- You do not have any other health condition that would prevent you from receiving the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
This trial tests adding tislelizumab (an immune medicine) to standard first-line chemotherapy for people age 60 and older with newly diagnosed classic Hodgkin lymphoma. The goal is to improve how well treatment works while adapting the plan for older adults.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This study looks at how a type of immune cell aging (called 'immunological senescence') might affect how well the drug pembrolizumab works in people whose Hodgkin lymphoma has come back or not responded to treatment.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.